The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.
News|Videos|October 30, 2026
September 2026 FDA Round Up
Author(s)Louie Pasculli
Fact checked by: Marco Meglio
NeurologyLive recaps September 2026 FDA approvals and their potential implications for the evolving treatment landscape across neurology. [WATCH TIME: 3 minutes]
Advertisement
WATCH TIME: 3 minutes | Captions are auto-generated and may contain errors.
September brought several notable developments in the neurology treatment landscape, with the FDA issuing approvals across a range of neurologic conditions. These decisions reflect continued progress in developing new therapeutic approaches for patients with both common and rare neurologic diseases.
Among the month's developments were advances in treatment options for Parkinson disease, as well as regulatory milestones for several rare neurologic conditions. Collectively, these decisions highlight the continued expansion of the therapeutic landscape and the growing range of approaches being evaluated to address underlying disease mechanisms and improve patient outcomes.
In this video, NeurologyLive® Assistant Editor Louie Pasculli recaps the major FDA neurology news from September 2026, discussing the clinical significance of these decisions and what they could mean for clinicians and patients.
Advertisement
Related to this article
Clene has filed an NDA seeking accelerated approval of CNM-Au8 for ALS, following 2 missed primary trial endpoints and years of evolving FDA guidance.
Shaida Khan, DO, associate professor of neurology at UT Southwestern Medical Center, reflected on a recent NeurologyLive Clinical Forum on generalized myasthenia gravis and discussed how FcRn and complement inhibitors are reshaping treatment algorithms for the disease.
Paul Melmeyer, MPP, Executive Vice President of Public Policy and Advocacy at the Muscular Dystrophy Association, discusses the Neuromuscular Advocacy Collaborative, its growing year-round presence, and what the group hopes to accomplish heading into the 2027 MDA Clinical and Scientific Conference.
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.
The phase 3 TRONTIER 1 and 2 trials will test whether trontinemab's faster brain entry and rapid amyloid clearance translate into slower clinical decline in early Alzheimer disease.
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with M. Scott Perry, MD. [LISTEN TIME: 15 minutes]
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Insights on the Updated 2026 AHA/ASA Stroke Rehabilitation Guidelines
2
World Stroke Day 2026: Closing the Gap Between Stroke Onset and the Emergency Call Number
3
Investigating the Genetic Link Between EBV and MS Risk: David A. Hafler, MD, FANA; Yoshiaki Yasumizu, MD, PhD
4
World Stroke Day: Preventing Perioperative Stroke With Predictive Tools
5